Loading...
Loading...
DRRX| Name | Value |
|---|---|
| Revenues | 2,171.0K |
| Cost of Revenue | 356.0K |
| Gross Profit | 1,815.0K |
| Operating Expense | 5,219.0K |
| Operating I/L | -3,404.0K |
| Other Income/Expense | -296.0K |
| Interest Income | 227.0K |
| Pretax | -3,700.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,700.0K |
DURECT Corporation is a biopharmaceutical company specializing in the research and development of medicines, including the ALZET product line, which offers osmotic pumps and accessories for research in laboratory animals. The company is also focused on the development of larsucosterol (DUR-928), a small molecule in Phase IIb clinical trial for the treatment of alcohol-associated hepatitis and completed Phase Ib clinical trial for nonalcoholic steatohepatitis. Additionally, DURECT offers POSIMIR, a post-surgical pain product, and Methydur for attention deficit hyperactivity disorder. The company generates revenue through direct sales of its products in the United States and international distribution partnerships.
